Who
Namandje Bumpus
Director
Company insider
Files Form 4 as: Director, Recursion Pharmaceuticals.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $56K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 17 Mar 2025
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $13K3,963 at $3.18 | filing |
| 18 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $13K3,963 at $3.18 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $16K4,386 at $3.54 | filing |
| 3 Jun 2026filed 4 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $16K4,386 at $3.54 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,016 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —11,008 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,099 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —36,549 at $0.00 | filing |
News
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Lifted to "Sell" by Wall Street ZenRXRX · dailypolitical.com · 18 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)RXRX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Namandje Bumpus; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.